Sign Up Today and Learn More About S-Alpha Therapeutics Stock
Invest in or calculate the value of your shares in S-Alpha Therapeutics or other pre-IPO companies through EquityZen's platform.
S-Alpha Therapeutics Stock (SATH)
S-Alpha Therapeutics engages in the research and development of health apps and digital therapeutics.
About S-Alpha Therapeutics Stock
Founded
2019
Industries
Messaging and Telecommunications, Advertising, Content and Publishing
S-Alpha Therapeutics Press Mentions
Stay in the know about the latest news on S-Alpha Therapeutics
Digital apparatus and application for cancer cachexia therapy and methods of …
patents • Feb 12, 2025
Antiviral digital device
patents • Feb 12, 2025
Correlating health conditions with behaviors for treatment programs in …
patents • Feb 12, 2025
Digital apparatus and application for treating mild cognitive impairment and …
patents • Feb 12, 2025
S-Alpha Therapeutics secures Series B funding for myopia-digital treatment
koreatechdesk • Mar 29, 2023
S-Alpha Therapeutics Management
Leadership team at S-Alpha Therapeutics
Chief Strategy Officer
Yongsun Lee
Co-Founder & CEO
SeungEun Choi
Join now and verify your accreditation status to gain access to:
- S-Alpha Therapeutics Current Valuation
- S-Alpha Therapeutics Stock Price
- S-Alpha Therapeutics Management
- Available deals in S-Alpha Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- S-Alpha Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- S-Alpha Therapeutics Revenue and Financials
- S-Alpha Therapeutics Highlights
- S-Alpha Therapeutics Business Model
- S-Alpha Therapeutics Risk Factors
- S-Alpha Therapeutics Research Report from SACRA Research
Trading S-Alpha Therapeutics Stock
How to invest in S-Alpha Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like S-Alpha Therapeutics through EquityZen funds. These investments are made available by existing S-Alpha Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell S-Alpha Therapeutics stock?
Shareholders can sell their S-Alpha Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 350K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 45K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
